Influence on Cough and Airway Symptoms by Oral Capsaicin

Summary

Study objectives

To establish whether an oral intake of Capsicum oleoresin; capsaicinoids expressed as 0.4 mg capsaicin (C18H27N03; Mw: 305.4) in each capsule (from chili extract) can desensitise the cough reflex and improve unexplained coughing.

Study period

* Estimated Start date (first patient enrolled) June 2019
* Estimated End date (last patient completed follow up) June 2020
* First data available for presentation September 2020

Investigational product/comparator

The formulation is prepared from Capsicum oleoresin. Each capsule will contend a dose corresponding to 0.4 mg capsaicin. All test methods are as per the European Pharmacopoeia for Capsicum oleoresin refined and standardised.

* The formulation is developed by Research Institutes of Sweden (RISE), Sodertalje, Sweden
* Supplier of raw material for the Capsicum oleoresin product/IMP: RANSOM; Ltd, London, UK
* Producer of capsules with Capsicum oleoresin and placebo: by Catalent Pharma Solutions, St Petersburg, Florida, USA
* Packing bottles of capsules with the investigational medical product (IMP) and placebo: by Apotek Produktion \& Laboratorier AB (APL), Stockholm, Sweden

Study design

Capsules, taken orally, with standardised doses of Capsicum oleoresin corresponding to 0.4 mg pure capsaicin (from chili extract) in each capsule in comparison to matched capsules with placebo (sorbitol and colorant), all capsules looking the same. Four weeks of active treatment is compared to four weeks of placebo. In between there is a wash out period of two weeks.

The time frame is 24 hours + 10 weeks. During the first 24 hours the patients carry a cough recorder (Leicester Cough Monitor - LCM) and then start with 4 weeks of active treatment or placebo. This is followed by 2 weeks of wash out and then the patients start with another 4 weeks of active treatment or placebo. After this the study ends.

Collaboration

Professor Alyn Morice MD, PhD, chief physician at Hull York Medical School, University of Hull, UK. Professor Surinder Birring MD, Senior Lecturer, specialist in respiratory medicine, Imperial College, London, UK. Associate professor Alastair Ross,PhD, Chalmers University of Technology, Gothenburg, Sweden.

Study center and number of subjects planned

All clinical trials take place at the asthma and allergy clinic, Sahlgrenska University Hospital, Gothenburg, Sweden from where 60 patients with chronic idiopathic cough (CIC) are recruited.

Conditions

• Cough

Interventions

DRUG

Capsicum Oleoresin

The soft gel capsules used in the study are easily digested in the stomach and contain standardised doses of 0,4 mg Capsicum oleoresin with the main component capsaicin (8-methyl-N-vanillyl-6-nonenamide) (from chili extract).

DRUG

Placebos

Soft gel capsules filled with placebo - sorbitol and colorant.

Sponsors & Collaborators

• Sahlgrenska University Hospital

  collaborator OTHER

• Vinnova

  collaborator OTHER_GOV

• Vastra Gotaland Region

  lead OTHER_GOV

Principal Investigators

• Eva Millqvist, MD, PhD · Vastra Gotaland Region

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

CROSSOVER

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-06-01

Primary Completion

2025-12-30

Completion

2026-06-15

Countries

• Sweden

Study Locations